Tranexamic acid

Generic Name
Tranexamic acid
Brand Names
Cyklokapron, Lysteda
Drug Type
Small Molecule
Chemical Formula
C8H15NO2
CAS Number
1197-18-8
Unique Ingredient Identifier
6T84R30KC1
Background

Tranexamic acid is a synthetic derivative of lysine used as an antifibrinolytic in the treatment and prevention of major bleeding. It possesses a similar mechanism of action to aminocaproic acid but is approximately 10-fold more potent.

It was first patented in 1957 and received its initial US approval in 1986.

Indication

Taken orally, tranexamic acid is indicated for the treatment of hereditary angioedema, cyclic heavy menstrual bleeding in premenopausal females, and other instances of significant bleeding in the context of hyperfibrinolysis. Given intravenously, tranexamic acid is indicated for short-term use (2-8 days) in patients with hemophilia to prevent or reduce bleeding following tooth extraction.

Associated Conditions
Bleeding, Heavy Menstrual Bleeding, Hereditary Angioedema (HAE)
Associated Therapies
-

American Trial Using Tranexamic Acid in Thrombocytopenia

Phase 3
Completed
Conditions
Interventions
First Posted Date
2015-10-19
Last Posted Date
2021-03-24
Lead Sponsor
University of Washington
Target Recruit Count
330
Registration Number
NCT02578901
Locations
🇺🇸

University of Washington, Seattle, Washington, United States

🇺🇸

University of North Carolina, Chapel Hill, North Carolina, United States

🇺🇸

University of Pittsburgh, Pittsburgh, Pennsylvania, United States

Investigation of Intravenous Tranexamic Acid With Anatomic and Reverse Total Shoulder Arthroplasty

First Posted Date
2015-10-07
Last Posted Date
2021-11-02
Lead Sponsor
Rush University Medical Center
Target Recruit Count
110
Registration Number
NCT02569658
Locations
🇺🇸

Rush University Medical Center, Chicago, Illinois, United States

Tranexamic Acid in Chronic Subdural Hematomas

Phase 2
Recruiting
Conditions
Interventions
First Posted Date
2015-10-05
Last Posted Date
2023-09-05
Lead Sponsor
Centre de recherche du Centre hospitalier universitaire de Sherbrooke
Target Recruit Count
130
Registration Number
NCT02568124
Locations
🇨🇦

University of Alberta Hospital, Edmonton, Alberta, Canada

🇨🇦

Centre Hospitalier Affilié Universitaire de Québec, Québec, Canada

🇨🇦

Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada

PeriOperative ISchemic Evaluation-3 Trial: A Pilot Study

First Posted Date
2015-09-11
Last Posted Date
2018-04-24
Lead Sponsor
McMaster University
Target Recruit Count
100
Registration Number
NCT02546648
Locations
🇨🇦

Juravinski Hospital, Hamilton, Ontario, Canada

🇨🇦

Hamilton General Hospital, Hamilton, Ontario, Canada

Tranexamic Acid Mechanisms and Pharmacokinetics in Traumatic Injury

First Posted Date
2015-08-31
Last Posted Date
2021-08-31
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
150
Registration Number
NCT02535949
Locations
🇺🇸

Barnes Jewish Hospital, Saint Louis, Missouri, United States

The Efficacy and Safety of Using Tranexamic Acid to Reduce Blood Loss In Simultaneous Bilateral Total Knee Arthroplasty

Phase 4
Completed
Conditions
Interventions
First Posted Date
2015-07-21
Last Posted Date
2016-03-04
Lead Sponsor
Xijing Hospital
Target Recruit Count
120
Registration Number
NCT02504125
Locations
🇨🇳

Xijing hospital, Xi'an, Shaanxi, China

Clinical Study to Assess the Equivalence of Tranexamic Acid vs Oxytocin in Reducing the PPH (TRANOXY2015)

Phase 3
Withdrawn
Conditions
Interventions
First Posted Date
2015-07-20
Last Posted Date
2024-02-08
Lead Sponsor
Azienda U.S.L. 1 di Massa e Carrara
Registration Number
NCT02503319

Evaluation of Intraarticular Tranexamic Acid to Reduction of Total Blood Loss Following Knee-Arthroplasty

First Posted Date
2015-04-28
Last Posted Date
2015-08-17
Lead Sponsor
Hvidovre University Hospital
Target Recruit Count
60
Registration Number
NCT02427412
Locations
🇩🇰

Hvidovre University Hospital, Hvidovre, Denmark

Acid Tranexamic Effectiveness in Reducing the Intraoperative Bleeding in Palatoplasty

Phase 4
Completed
Conditions
Interventions
First Posted Date
2015-04-21
Last Posted Date
2015-04-21
Lead Sponsor
Professor Fernando Figueira Integral Medicine Institute
Target Recruit Count
66
Registration Number
NCT02422056
© Copyright 2024. All Rights Reserved by MedPath